Drug Database
DI

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine (KD370 / KD 370 / Quintovac)

✓ Approved

Meiji Holdings · Vaccine · Vaccine

What is diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine?

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is a vaccine developed by Meiji Holdings. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesKD370, KD 370, Quintovac
CompanyMeiji Holdings
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Meiji Holdings

Therapeutic Indications

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved
Surgical and medical proceduresPolio immunisation✓ Approved

Related Research Articles

PubMedFrontiers in public health2026-07-25

Clinical characteristics and macrolide resistance analysis of pertussis in children: a retrospective study.

Zhang Huifen H, Yang Xiaoqing X, Guo Jiaowei J, Li Jiming J

Pertussis is mainly caused by Bordetella pertussis. Currently, no reports exist on the incidence of B. pertussis infection or on its patterns of macrolide resistance among pediatric cases in Xiamen, Fujian Province, China. The aim of this study was to determine the clinical characteristics and macrolide resistance patterns in pediatric pertussis. We retrospectively collected data from 968 children with pertussis between February 2021 and January 2025. Demographic characteristics, disease trends, clinical features, and macrolide resistance among outpatients and inpatients were analyzed. Most inpatients with pertussis were infants aged < 3 months, whereas most outpatients were school-aged children. Inpatients demonstrated significantly higher rates of leukocytosis, fever, co-infection, recent exposure to individuals with a cough, comorbid pneumonia, and macrolide use and experienced longer time from cough onset to confirmed diagnosis than did outpatients. The proportion of children who presented with spasmodic cough, violent coughing with facial flushing, inspiratory whoop, tachypnea, cyanosis, hypoxemia, and respiratory failure, as well as the average hospital stay, was significantly higher among children with severe pertussis than among those with common pertussis. Age younger than 3 months, being unvaccinated, co-infection, leukocytosis, lymphocytosis, spasmodic cough, facial flushing, inspiratory whoop, tachypnea, and cyanosis were risk factors for severe pertussis. Macrolides were the main antibiotics prescribed for children with pertussis. The detection rate of drug-resistant mutation sites was 77.52% in outpatients and 92.50% in inpatients. It is necessary to enhance the vaccination of pertussis for special populations, including women in the later pregnancy stages and school-aged children. Children with pertussis who have risk factors should be monitored to identify severe cases. The empirical use of macrolides for pertussis treatment is effective in most cases; alternative agents should be considered if the response is suboptimal, especially when drug-resistant mutation sites are identified.

PMID 42500007
Read full article →
PubMedAnnals of intensive care2026-07-25

A contemporary overview of severe community-acquired bacterial infections in pediatric intensive care units.

Levy Michael M, Mary Annelise A, Cour Andlauer Fleur F, Rousseaux Jeremie J et al.

Community-acquired bacterial infections (CABIs) remain a leading cause of pediatric morbidity and mortality. This study aimed to provide a contemporary description of pediatric CABIs requiring admission to pediatric intensive care units (PICUs) in France. The CAPRICE study is a prospective, multicenter cohort including all children with suspected CABIs who were admitted to 28 French PICUs from January to December 2024. Demographic, clinical, microbiologic, and outcome data were prospectively collected. The primary outcome was mortality at day 28 and secondary outcomes included sequelae at day 28, PICU length of stay, and total hospital stay. Independent predictors of mortality were identified by multivariable logistic regression. Among 897 children, the median age was 1.9 years (IQR 0.2-8.8); 55% were male, and 30% had a chronic condition. The leading infections were lower respiratory tract infection (43%), meningitis (20%), and ear-nose-throat infections (13%). Septic shock occurred in 17% of cases. A pathogen was identified in 89% of cases: Bordetella pertussis (22%) and Mycoplasma pneumoniae (15%) were predominant, followed by Streptococcus pneumoniae (13%), and Staphylococcus aureus (11%). In all, 34% patients had viral co-infection and 70% required organ support. Overall mortality was 7%, increasing to 19% with septic shock. Independent predictors of death included multiple organ failure, meningitis, and B. pertussis infection. Sequelae occurred in 15% of survivors. Severe CABIs in French PICUs in 2024 were mainly caused by B. pertussis and M. pneumoniae, followed by S. pneumoniae and S. aureus. Mortality and morbidity of these infections remain substantial.

PMID 42500454
Read full article →
PubMedJournal of environmental sciences (China)2026-07-25

Bloom of Blixaea quinquecornis (Abé) Gottschling (Dinophyceae) with Chaetoceros tenuissimus Meunier in the South Atlantic: Morphology, molecular characterization, and toxins.

Guennes Marcella M, Goulart Amanda Santos AS, Salgueiro Fabiano F, Lange Priscila Kienteca PK et al.

Blixaea quinquecornis (Abé) Gottschling is a monotypic and cosmopolitan marine dinoflagellate with a Chaetoceros derived tertiary plastid (a dinotom). An extensive bloom of B. quinquecornis that covered 80 km² and extended to 15 km away from the coastline occurred at the Brazilian Northeast coast. B. quinquecornis abundances of 2.3 × 10⁶ cells/L were recorded, causing water discoloration. Molecular analysis of field cells confirmed the identity of B. quinquecornis and the diatom Chaetoceros tenuissimus Meunier, that was found in close association with the dinoflagellate. B. quinquecornis presented the typical morphology of the species, with a conical epitheca, and hypotheca with four antapical spines. Mean cell length was 23.3 ± 2.8 µm and width 19.5 ± 2.8 µm. Toxin screening (PSTs, palytoxins, brevetoxins) showed negative results, though the presence of a putative new palytoxin analogue cannot be excluded. This study presented the first comprehensive characterization of B. quinquecornis, combining morphological description, molecular phylogeny and toxin screening, and contributed with the second molecular sequence of this species. It is noteworthy that B. quinquecornis was found in close association with Chaetoceros tenuissimus, the original diatom-derived tertiary plastid in B. quinquecornis. Future research should prioritize establishing cultures of B. quinquecornis to definitively resolve the nature of its plastid association (kleptoplastidy vs. permanent endosymbiosis) and to enable more comprehensive toxin biosynthesis investigations.

PMID 42498397
Read full article →
PubMedImmunological reviews2026-07-25

The Dual Role of Preexisting Immunity in Influenza: Protective Recall Versus Constraint of Novel Responses.

Fox Annette A, Zhu Ziheng Z, Sánchez-Ovando Stephany S

Preexisting immunity to influenza confers rapid protection against antigenically matched viruses but can also constrain responses to drifted variants. This review asks when and why prior infection or vaccination is protective versus detrimental, and which biological mechanisms-epitope masking by circulating antibody, inhibitory FcγRIIb signaling, and competitive dominance by affinity-matured memory B cells-drive these outcomes. We synthesize human cohort, serological, and vaccine-effectiveness data with mechanistic mouse and fate-mapping studies to explore how vaccine formulation, antigen dose, antigenic distance and T cell help modulate the balance between memory recall and recruitment of naïve B cells. Finally, we outline strategies (higher dose, adjuvants, multivalent display, and considered strain selection) to restore de novo responses against escape epitopes and improve vaccine performance.

PMID 42499177
Read full article →
PubMedJournal of the International AIDS Society2026-07-25

Defining the Efficacy of Meningococcal B Vaccines Against Gonococcal Acquisition: The Current Landscape.

Seib Kate L KL, Grulich Andrew E AE

Gonorrhoea is a major global sexually transmitted infection, with rising incidence and increasing antimicrobial resistance threatening current control strategies. If untreated, Neisseria gonorrhoeae can lead to severe reproductive health sequelae. Gonorrhoea is also linked to increased HIV acquisition and transmission. There is currently no vaccine licensed to prevent gonorrhoea. However, observational evidence suggests that outer membrane vesicle-based serogroup B meningococcal vaccines, including the four-component meningococcal B (4CMenB) vaccine, confer partial cross-protection against gonorrhoea. We discuss observational studies and randomized controlled trials (RCTs) focused on defining the efficacy of 4CMenB against gonorrhoea. Observational studies from multiple settings have reported an association between receipt of 4CMenB vaccine and reduced gonorrhoea risk, with a meta-analysis estimating a 38% reduction in risk. Neisseria meningitidis and N. gonorrhoeae are closely related bacteria that share numerous antigens, making cross-protection biologically plausible. Based on observational data, 4CMenB immunization programmes have been implemented in two countries with the aim of preventing gonorrhoea. However, three RCTs have recently shown that 4CMenB is not effective in preventing gonorrhoea in gay, bisexual and other men at high risk of acquisition. Several RCTs are ongoing, looking at efficacy in different populations, including women and people at lower risk of acquisition. The different outcomes between the observational studies and RCTs may be due to a range of known and unknown confounding factors, and differences in the populations considered in the different studies. Current evidence from RCTs does not support the use of 4CMenB to prevent gonorrhoea in gay and bisexual men at high risk of acquisition. Results from ongoing RCTs will be critical to determine whether vaccine efficacy varies by population or epidemiological context and to inform future gonorrhoea vaccine policy and development.

PMID 42499182
Read full article →
PubMedHospital pharmacy2026-07-25

Distribution and Characteristics of Vaccine Adverse Events: Analysis of Over 2 Million Individual Case Safety Reports.

Castellana Eleonora E, Chiappetta Maria Rachele MR

To describe the distribution and characteristics of adverse events following immunization (AEFI) using a large US pharmacovigilance database. A retrospective descriptive analysis of Individual Case Safety Reports (ICSRs) from the FDA AEMS database (January 2017-March 2026) was conducted. Reports were analyzed by vaccine type, adverse event terms, demographics, reporting year, and reporter category. A total of 2 169 603 ICSRs were identified, with 44.0% classified as serious. COVID-19 vaccines accounted for 78.4% of reports, reflecting mass vaccination campaigns. The most frequently reported events were headache (12.8%), pyrexia (11.8%), and fatigue (11.1%), predominantly non-serious and consistent with known reactogenicity profiles. Reporting peaked in 2021 (48.8%). Females accounted for 60.6% of reports. Non-COVID vaccines contributed substantially fewer reports. Most vaccine-associated adverse events were mild and expected. Findings support a favorable benefit-risk profile and highlight the importance of continuous pharmacovigilance systems for vaccine safety monitoring.

PMID 42500260
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine